Literature DB >> 28733758

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.

Manisha Gupte1, Prachi Umbarkar1, Hind Lal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28733758      PMCID： PMC5717761          DOI： 10.1007/s10557-017-6741-2

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  17 in total

1.  Heart failure: SGLT2 inhibitors and heart failure -- clinical implications.

Authors:  Itamar Raz; Avivit Cahn
Journal:  Nat Rev Cardiol       Date:  2016-03-10       Impact factor: 32.419

2.  The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.

Authors:  Michael Joubert; Benoît Jagu; David Montaigne; Xavier Marechal; Angela Tesse; Audrey Ayer; Lucile Dollet; Cédric Le May; Gilles Toumaniantz; Alain Manrique; Flavien Charpentier; Bart Staels; Jocelyne Magré; Bertrand Cariou; Xavier Prieur
Journal:  Diabetes       Date:  2017-01-04       Impact factor: 9.461

3.  Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.

Authors:  Nadjib Hammoudi; Dongtak Jeong; Rajvir Singh; Ahmed Farhat; Michel Komajda; Eric Mayoux; Roger Hajjar; Djamel Lebeche
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

4.  Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?

Authors:  Xingjuan Shi; Subodh Verma; Junghwa Yun; Koroboshka Brand-Arzamendi; Krishna K Singh; Xiangdong Liu; Ankit Garg; Adrian Quan; Xiao-Yan Wen
Journal:  Mol Cell Biochem       Date:  2017-04-08       Impact factor: 3.396

Review 5.  From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.

Authors:  Harold Bays
Journal:  Curr Med Res Opin       Date:  2009-03       Impact factor: 2.580

6.  Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.

Authors:  Hiroaki Kusaka; Nobutaka Koibuchi; Yu Hasegawa; Hisao Ogawa; Shokei Kim-Mitsuyama
Journal:  Cardiovasc Diabetol       Date:  2016-11-11       Impact factor: 9.951

7.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Authors:  Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici
Journal:  Circulation       Date:  2017-05-18       Impact factor: 29.690

8.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Authors:  David Fitchett; Bernard Zinman; Christoph Wanner; John M Lachin; Stefan Hantel; Afshin Salsali; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  Eur Heart J       Date:  2016-01-26       Impact factor: 29.983

9.  Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.

Authors:  Jagdeep S S Singh; Amir Fathi; Keeran Vickneson; Ify Mordi; Mohapradeep Mohan; J Graeme Houston; Ewan R Pearson; Allan D Struthers; Chim C Lang
Journal:  Cardiovasc Diabetol       Date:  2016-07-15       Impact factor: 9.951

10.  Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.

Authors:  Antonius Baartscheer; Cees A Schumacher; Rob C I Wüst; Jan W T Fiolet; Ger J M Stienen; Ruben Coronel; Coert J Zuurbier
Journal:  Diabetologia       Date:  2016-10-17       Impact factor: 10.122
View more
  2 in total

1.  Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians.

Authors:  Guodong Pan; Mandar Deshpande; Haiyan Pang; Suresh Selvaraj Palaniyandi
Journal:  Eur J Pharmacol       Date:  2018-09-19       Impact factor: 5.195

2.  Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.

Authors:  Salva R Yurista; Herman H W Silljé; Harry van Goor; Jan-Luuk Hillebrands; Hiddo J L Heerspink; Luiz de Menezes Montenegro; Silke U Oberdorf-Maass; Rudolf A de Boer; B Daan Westenbrink
Journal:  Cardiovasc Drugs Ther       Date:  2020-06       Impact factor: 3.947
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.